Deferred Tax Assets, Valuation Allowance of Protalix BioTherapeutics, Inc. from 31 Dec 2011 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Protalix BioTherapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2024.
Protalix BioTherapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $50,665,000, a 1.8% decline year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Protalix BioTherapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$50,665,000	-$953,000	-1.8%	31 Dec 2024	10-K	17 Mar 2025	2024	FY
Q4 2023	$51,618,000	-$6,932,000	-12%	31 Dec 2023	10-K	17 Mar 2025	2024	FY
Q4 2022	$58,550,000	-$2,970,000	-4.8%	31 Dec 2022	10-K	17 Mar 2025	2024	FY
Q4 2021	$61,520,000	-$2,240,000	-3.5%	31 Dec 2021	10-K	14 Mar 2024	2023	FY
Q4 2020	$63,760,000	+$4,252,000	+7.1%	31 Dec 2020	10-K	31 Mar 2022	2021	FY
Q4 2019	$59,508,000	+$3,895,000	+7%	31 Dec 2019	10-K	30 Mar 2021	2020	FY
Q4 2018	$55,613,000	-$2,755,000	-4.7%	31 Dec 2018	10-K	12 Mar 2020	2019	FY
Q4 2017	$58,368,000	+$16,333,000	+39%	31 Dec 2017	10-K	18 Mar 2019	2018	FY
Q4 2016	$42,035,000	+$4,996,000	+13%	31 Dec 2016	10-K	06 Mar 2018	2017	FY
Q4 2015	$37,039,000	-$3,072,000	-7.7%	31 Dec 2015	10-K	16 Mar 2017	2016	FY
Q4 2014	$40,111,000	+$1,685,000	+4.4%	31 Dec 2014	10-K	08 Mar 2016	2015	FY
Q4 2013	$38,426,000	+$6,890,000	+22%	31 Dec 2013	10-K	12 Mar 2015	2014	FY
Q4 2012	$31,536,000	+$17,772,000	+129%	31 Dec 2012	10-K	13 Mar 2014	2013	FY
Q4 2011	$13,764,000			31 Dec 2011	10-K	28 Feb 2013	2012	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.